$SLNO
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Healthcare
Sector
Biotechnology
Industry
Anish Bhatnagar
CEO
115
Employees
$33.48
Current Price
$2.31B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 6 | $429,344.42 | 14,104 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 6 | $429,344.42 | 14,104 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 6 | $429,344.42 | 14,104 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 6 | $429,344.42 | 14,104 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 27, 2026 | Manning Meredith Chief Commercial Officer | Sale | 2,100 | $31.04 | $65,180.64 | View Details |
| Mar 27, 2026 | Manning Meredith Chief Commercial Officer | Sale | 558 | $31.72 | $17,699.03 | View Details |
| Mar 27, 2026 | Manning Meredith Chief Commercial Officer | Sale | 4,864 | $30.04 | $146,099.97 | View Details |
| Mar 27, 2026 | Huang Michael F. Sr. VP of Clinical Development | Sale | 488 | $31.72 | $15,478.73 | View Details |
| Mar 27, 2026 | Huang Michael F. Sr. VP of Clinical Development | Sale | 4,256 | $30.04 | $127,837.47 | View Details |
| Mar 27, 2026 | Huang Michael F. Sr. VP of Clinical Development | Sale | 1,838 | $31.04 | $57,048.58 | View Details |
2 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated$0.64
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated$0.64
ActualN/A
Revenue
Estimated$88.55M
ActualN/A